ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling

The type III receptor tyrosine kinase FLT3 is one of the most commonly mutated oncogenes in acute myeloid leukemia (AML). Inhibition of mutated FLT3 in combination with chemotherapy has displayed promising results in clinical trials. However, one of the major obstacles in targeting FLT3 is the devel...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Kazi, Julhash U., Rupar, Kaja, Marhäll, Alissa, Moharram, Sausan A., Khanum, Fatima, Shah, Kinjal, Gazi, Mohiuddin, Nagaraj, Sachin Raj M., Sun, Jianmin, Chougule, Rohit A., Rönnstrand, Lars
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355336/
https://ncbi.nlm.nih.gov/pubmed/28086240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14577
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars